Ireland
--:--IST
Latest
Clinical Trials in France / NCT03690856
Active, not recruiting Not applicable

Clinical and Neurobiological Profile Predictive of Pejorative Outcome of Depression

NCT03690856 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2019-11-08
Last updated
2026-06-12

Condition(s) studied

Depression

Investigational drug(s) / intervention(s)

inflammatory, neuropsychological and neuroimaging assessment

inflammatory, neuropsychological and neuroimaging assessment: Acts add by research: pregnancy test; Centralized: IL1, IL6, TNF Neuropsychologic tests at M6 and M24: Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)

Study summary

Depression is a frequent disease which can be marked by therapeutic resistance. It is described as one of the most disabling disease with high cost for society. World Health Organization pointed out that 350 million people are suffering from depression in the world. This pathology is considered underdiagnosed, with inadequate care resources and stigmatization.

There is a wide range of evidence in current literature that anxiety is one of the most important factors involved in biological mechanism of treatment resistance in depression. To date, there is a lack of knowledge on this topic. A better understanding of the role of anxiety in the maintenance of depressive state will allow to i) identify quickly and more accurately patients at risk of pejorative evolution and ii) develop specific therapeutics targeting this dimension which remain badly controlled with actual therapeutics.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men and women older than 18 years-old; * Suffering from a Mood Depressive Episode ( according to DSM IV criteria), and-or Mood Depressive recurrent depression (unipolar or bipolar) (\<at stage 3 of Thase and Rush). Treatment resistance will be assessed using Thase an Rush Classification and measured with Maudsley Staging Method (Fekadu et al., 2009); * MADRS score 15; * Capacity for the patient to receive information on protocol; * Patient who gave their consent to the protocol. Exclusion Criteria: * Contra-indication to MRI * Patients under social protection or hospitalized without their consent * Patients suffering from a psychiatric comorbidity such as: schizophrenia, schizo-affective disorder, personality disorder, actual addiction, anorexia-bulimia, obsessive-compulsive disorder; * Patients suffering from severe intercurrent disease with health prognosis engaged; * Patients suffering from neurological comorbidity such as: any neurodegenerative disorder (Alzheimer disease, Parkinson disease, Lewy's body disease, multiple sclerosis), any intracranial expansive process. * Patients with an history of severe cranial injury (with coma); * Patients with abnormal cerebral MRI.

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
CHU angers Angers France
CHU de Brest - Hôpital de Bohars Brest France
CHU de Nantes - Hotel-Dieu Nantes France
CH Henri Laborit Poitiers France
CH Guillaume Regnier Rennes France
EPSM du Morbihan Saint-Avé France
CH Saint-Malo St-Malo France
CHU de Tours, Clinique Psychiatrique Universitaire Tours France

More Rennes University Hospital trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03690856 on ClinicalTrials.gov ↗ ← All trials in France